EGFR and neoplasm: A novel nanoparticle‐based tri‐specific NKCE (nano‐TriNKCE) targeting EGFR‐overexpressing tumours has been developed using a PEG–PLGA matrix, modified with cetuximab and co‐functionalised with anti‐CD16 and anti‐4‐1BB antibodies.